180 related articles for article (PubMed ID: 10912625)
41. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
42. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
43. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
44. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
45. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
[TBL] [Abstract][Full Text] [Related]
46. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
[TBL] [Abstract][Full Text] [Related]
47. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
48. [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy].
Pivnik AV; Rastrigin NA; Moiseeva TN; Lutsenko IN; Dudarova RG; Shavlokhov VS; Efimov IV; Kozhurin SV; Shitareva IV; Gemdzhian EG; Tsyba NN; Kolosova LIu; Melikian AL; Skidan NI; Pan'shin GA; Sotnikov VM; Dotsenko PV; Nechistiuk AV
Ter Arkh; 2006; 78(8):57-62. PubMed ID: 17078219
[TBL] [Abstract][Full Text] [Related]
49. Circulating immune complexes (CIC) in Hodgkin's disease. I. Levels and two-dimensional analysis.
Nerurkar AV; Advani SH; Gothoskar BP
Neoplasma; 1989; 36(2):199-205. PubMed ID: 2716924
[TBL] [Abstract][Full Text] [Related]
50. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
51. Influence of splenectomy on the levels of circulating immune complexes (CIC) in Hodgkin's disease (HD).
Nerurkar AV; Advani SH; Gothoskar BP
Neoplasma; 1987; 34(1):89-93. PubMed ID: 3561608
[TBL] [Abstract][Full Text] [Related]
52. Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone.
Gibbs GE; Peterson BA; Kennedy BJ; Vosika G; Bloomfield CD
Arch Intern Med; 1981 Jun; 141(7):897-900. PubMed ID: 7235809
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of circulating immune complexes in malignant tumours of head and neck.
Das TK; Aziz M; Rattan A; Sherwani R
J Indian Med Assoc; 1995 Jan; 93(1):3-7. PubMed ID: 7759908
[TBL] [Abstract][Full Text] [Related]
54. [Clinical and hematological characteristics and MOPP tolerance of patients with Hodgkin's lymphoma in the bone marrow].
Fiacchini M; Lauria F; Mazza P; Tura S
Haematologica; 1982 Jun; 67(3):394-401. PubMed ID: 6814996
[No Abstract] [Full Text] [Related]
55. Nitroblue tetrazolium test in patients with Hodgkin's disease in the course of chemotherapy.
Kemona H; Wysocka J; Prokopowicz J; Kiluk S
Neoplasma; 1987; 34(1):107-13. PubMed ID: 3561600
[TBL] [Abstract][Full Text] [Related]
56. Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients.
Aziz M; Das TK; Rattan A
Indian J Cancer; 1997 Sep; 34(3):111-20. PubMed ID: 9491672
[TBL] [Abstract][Full Text] [Related]
57. Clinical utility and monitoring of breast cancer by circulating immune complexes.
Dass TK; Aziz M; Rattan A; Tyagi SP
Indian J Pathol Microbiol; 1992 Oct; 35(4):298-307. PubMed ID: 1344219
[TBL] [Abstract][Full Text] [Related]
58. Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features.
Mozzana R; Baldini L; Neri A; Cortelezzi A; Radaelli F; Colajori E; Polli EE
Boll Ist Sieroter Milan; 1982; 61(4):324-9. PubMed ID: 6927220
[TBL] [Abstract][Full Text] [Related]
59. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL).
Haase R; Vilser C; Mauz-Körholz C; Hasenclever D; Kluge R; Ruschke K; Borkhardt A; Seeger K; Lehrnbecher T; Kulozik A; Rößler J; Burdach S; Jürgens H; Körholz D
Klin Padiatr; 2012 Oct; 224(6):377-81. PubMed ID: 23047832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
